Avoro Capital Advisors Reduces $15M in Autolus Therapeutics plc ($AUTL)
Avoro Capital Advisors sells its entire stake in AUTL, shedding 9.91 million shares.
Key Points
- Avoro Capital Advisors sold its entire stake of 9,910,642 shares in AUTL, as per the latest 13F filing.
- Shares of AUTL were trading at $1.56, with other institutional investors like MAK Capital One LLC increasing their positions.
- Analysts from Needham and HC Wainwright & Co. maintain a 'buy' rating on AUTL, with price targets around $10.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Avoro Capital Advisors has completely exited its position in AUTL, according to its latest 13F filing with the SEC. The fund sold all 9,910,642 shares it previously held, leaving it with no remaining stake. This move represents a 100% reduction in its holdings.
What Changed in Avoro Capital Advisors' AUTL Position
Avoro Capital Advisors sold its entire holding of 9,910,642 shares in AUTL, reducing its stake to zero. This complete exit marks a significant change from its previous position, where the fund held nearly 10 million shares.
Other Institutional Activity in AUTL
Other institutional investors have shown varied interest in AUTL. MAK Capital One LLC increased its holdings by 3,616,144 shares, bringing its total to 33,621,487 shares valued at approximately $46.4 million. Blackstone Inc. maintained its position with 20,485,611 shares worth about $28.3 million. Meanwhile, Armistice Capital, LLC reduced its holdings by 1,700,000 shares, ending with 15,800,000 shares valued at $21.8 million.
Autolus Therapeutics plc Stock Down 33.3%
Shares of AUTL traded at $1.56. The stock's performance and market dynamics are of interest to investors and analysts alike, especially following Avoro Capital Advisors' recent exit.
Insider Buying and Selling at Autolus Therapeutics plc
Insider Martin Pule sold 698,741 shares on September 16, 2024, at an average price of $4.00 and $4.23 per share, under a planned Rule 10b5-1 trading plan.
Analysts Set New Price Targets
Analysts remain optimistic about AUTL. On May 14, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $10 price target. Similarly, Mizuho and Needham reiterated their 'buy' ratings with the same target. Wells Fargo also maintained a 'buy' rating with a lower target of $5.
About AUTL
AUTL operates in the biotechnology sector, focusing on the development and commercialization of innovative therapies. The company is involved in advancing treatments for various diseases, leveraging its proprietary technology platform.
Bottom Line
Avoro Capital Advisors' decision to sell its entire stake in AUTL is a notable move, reflecting its updated investment strategy. Investors often track such changes to gauge market sentiment, though 13F filings are historical and may not represent current positions. AUTL continues to attract attention from other institutional investors and analysts maintaining positive ratings.
Get Autolus Therapeutics plc alerts
New 13F filings, insider trades, and analyst moves on $AUTL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.